Literature DB >> 1426206

A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1.

E Dompeling1, C P van Schayck, J Molema, R Akkermans, H Folgering, P M van Grunsven, C van Weel.   

Abstract

Various indices are used to express the bronchodilating response. It is unclear, however, which index is most informative. The aim of this study was to compare six expressions of the bronchodilating response and to examine: 1) the independence of the prebronchodilator forced expiratory volume in one second (FEV1); and 2) the reproducibility of the bronchodilating response. Bronchodilating responses (increases in FEV1 60 min after salbutamol 400 micrograms and ipratropium bromide 80 micrograms) on six test occasions, during two years, of 183 patients (72 asthma, 111 chronic obstructive pulmonary disease (COPD)) from a large bronchodilator intervention study were used. The dependence of the prebronchodilator FEV1 was investigated both between patients (cross-sectional analysis) and within patients (longitudinal analysis) by means of linear regression analysis. The reproducibility of the bronchodilating response was calculated by means of the coefficients of variation (CVs) of the six bronchodilating responses during two years. The CVs of the six expression indices were compared by analysis of variance (ANOVA). No index was independent of the prebronchodilator FEV1. However, some indices were significantly more dependent on the prebronchodilator lung function and, therefore, less reproducible than others. The "% initial" index (change as a percentage of the prebronchodilator value) was the most dependent on the prebronchodilator lung function and had the worst reproducibility (CV ranged from 50-61%). The "% possible" (change as a percentage of the predicted minus prebronchodilator value) and "% achievable" (change as a percentage of the maximal postbronchodilator minus prebronchodilator value) indices were the least dependent on the prebronchodilator value and had the highest reproducibility (CV ranging from 34-53%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1426206

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

1.  Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge.

Authors:  E Dompeling; A M Oudesluys-Murphy; H M Janssens; W Hop; J G Brinkman; R N Sukhai; J C de Jongste
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

2.  Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations.

Authors:  Jocelyn R Grunwell; Khristopher M Nguyen; Alice C Bruce; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2019-10-12

3.  The role of coping resources and coping style in quality of life of patients with asthma or COPD.

Authors:  A E Hesselink; B W J H Penninx; M A G Schlösser; H A H Wijnhoven; D A W M van der Windt; D M W Kriegsman; J Th M van Eijk
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

4.  Random variation of inspiratory lung function parameters in patients with COPD: a diagnostic accuracy study.

Authors:  Frank J Visser; Sunil Ramlal; Ben Pelzer; P N Richard Dekhuijzen; Yvonne F Heijdra
Journal:  BMC Pulm Med       Date:  2010-05-14       Impact factor: 3.317

5.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease.

Authors:  P M A Calverley; P S Burge; S Spencer; J A Anderson; P W Jones
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

6.  Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group.

Authors:  H A Kerstjens; P L Brand; P H Quanjer; B A van der Bruggen-Bogaarts; G H Koëter; D S Postma
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

7.  Terbutaline in COPD comparison between Turbuhaler and chlorofluorocarbon (CFC) inhaler.

Authors:  H Formgren; A Sjökvist; E Ståhl; J E Wirén
Journal:  Lung       Date:  1994       Impact factor: 2.584

8.  Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis.

Authors:  H Koyama; K Nishimura; T Mio; A Ikeda; N Sugiura; T Izumi
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

9.  Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study.

Authors:  Wan C Tan; William M Vollmer; Bernd Lamprecht; David M Mannino; Anamika Jithoo; Ewa Nizankowska-Mogilnicka; Filip Mejza; Thorarinn Gislason; Peter G J Burney; A Sonia Buist
Journal:  Thorax       Date:  2012-04-29       Impact factor: 9.139

10.  Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma.

Authors:  Daphne C Richter; James R Joubert; Haylene Nell; Mace M Schuurmans; Elvis M Irusen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.